Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of Neuroblastoma

Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of Neuroblastoma

Despite major advances in pediatric cancer research, there has been only modest progress in the survival of children with high risk neuroblastoma (HRNB). The long term survival rates of HRNB in the United States are still only 30-50%. Due to resistance that often develops during therapy, developmen...

Full description

Bibliographic Details
Main Authors: Nirupama eSabnis, Suraj ePratap, Paul eBowman, Irina eAkopova, Andras G Lacko
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-03-01
Series:Frontiers in Pediatrics
Subjects:
Nanoparticles
Neuroblastoma
Drug delivery
rHDL
Fenretinide · All-trans Retinoic acid (ATRA)
Online Access:http://journal.frontiersin.org/Journal/10.3389/fped.2013.00006/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fped.2013.00006/full

Similar Items